Why build a matrix rather than read summaries
Reading two descriptions in sequence compares them on whichever attributes each description happened to emphasise. A matrix compares them on the attributes you chose, and shows the gaps where information is missing rather than letting an omission pass as a neutral.
The blanks are often the most informative cells. Two compounds compared on evidence quality where one column is empty have told you something the prose descriptions did not.
Which attributes are worth a column
Mechanism, evidence quality, regulatory status, half-life, typical purity, and cost per milligram cover most sourcing and planning questions. Physical properties, molecular weight, solubility class, storage requirement, cover the handling ones.
The choice of columns is the analysis. A matrix comparing three compounds on price and nothing else has answered a price question and implied it answered a broader one.
- •Mechanism and target
- •Evidence quality, ideally with the strongest study design named
- •Regulatory status by jurisdiction
- •Half-life and administration frequency implied by it
- •Molecular weight, solubility class and storage requirement
- •Typical purity and cost per milligram
Comparing evidence honestly
The most common distortion in a peptide comparison is treating preclinical and clinical evidence as points on one scale. They are not: an animal result and a randomised trial answer different questions, and averaging them into a single rating loses exactly the distinction that matters.
Recording the strongest study design alongside any rating keeps that visible. A compound rated moderate on the strength of consistent animal data and one rated moderate on a single small human trial are in different positions.
What a matrix cannot do
It cannot weigh the attributes for you. A compound that wins on four columns and loses on the one that matters most to your work has not won.
It also cannot compensate for the columns you did not include. The discipline is in choosing the attributes before filling the cells, rather than choosing the attributes that make the comparison come out.
How to build a useful comparison matrix
Choose the attributes first, fill every cell or mark it unknown, and cite the source for anything contestable.
- Choose the attributes before the compounds. Deciding what matters before looking at the candidates is what stops the column set from being selected to favour an answer.
- Use consistent units and scales. Half-life in hours throughout, cost per milligram in one currency, purity as a percentage with its method. A column comparing different units is not a comparison.
- Mark unknowns as unknown. An empty cell and a cell marked unknown read differently. The second is a finding; the first looks like an oversight.
- Separate evidence type from evidence strength. Record the strongest study design as well as any rating, so preclinical and clinical evidence are not collapsed onto one axis.
- Cite anything contestable. A matrix without sources is a set of assertions in a grid. With them it is a document someone else can check.
What this method cannot tell you
- •It does not weight attributes. Which column matters most is a judgement the table cannot make.
- •It is only as good as the cells. An authoritative-looking grid of unsourced figures is worse than prose, because the layout implies rigour.
- •It compares attributes, not suitability for a specific purpose.
- •Regulatory status and pricing both change, so a matrix has a shelf life.
Comparison matrix builder: frequently asked questions
A table with compounds as rows and attributes as columns, so several candidates can be compared on the same criteria rather than on whatever each description emphasised.
For a sourcing or planning decision:
- •Mechanism and target
- •Evidence quality and the strongest study design behind it
- •Regulatory status in your jurisdiction
- •Half-life
- •Molecular weight, solubility class and storage requirement
- •Typical purity and cost per milligram
Because choosing them afterwards invites selecting the attributes on which a preferred candidate performs well.
Deciding what matters first is the discipline that makes the comparison honest.
As unknown, explicitly. A blank cell reads as an oversight; a cell marked unknown reads as a finding about the compound.
Only where comparable evidence exists, which for most research peptides it does not. Cross-trial comparisons between different populations and protocols are unreliable.
Head-to-head trials are the only clean comparison, and they are rare outside approved therapeutics.
Because an animal result and a randomised trial answer different questions, and collapsing them onto one scale loses the distinction that matters most.
Two compounds both rated moderate can be in entirely different evidential positions.
Where the decision involves buying, yes, as cost per milligram of actual peptide rather than price per vial.
It is one column among several. A matrix that reduces to a price comparison has answered a narrower question than it appears to.
In consistent units, and noting whether each figure is a terminal elimination half-life or a distribution one.
The practical implication is the administration interval it permits, which the half-life plotter makes visible.
Yes, and by jurisdiction, because status varies substantially between them.
The regulatory status checker summarises the major jurisdictions per compound.
Three to five is the range that stays readable. Beyond that the table becomes a reference document rather than a decision aid.
For anything contestable, yes. A grid of unsourced figures is worse than prose, because the layout implies a rigour the content does not have.
No. It organises the comparison; the weighting is yours. A compound winning four columns and losing the one that matters has not won.
Whenever the underlying facts move. Regulatory status and pricing change frequently; mechanism and molecular weight do not.
Where reliable safety data exists, yes, and for most research peptides it does not, which is itself worth recording as a cell.
Absence of reported adverse effects is not evidence of safety when nobody has looked systematically.
The table can be copied out of the page. There is no dedicated export, since the matrix is a working aid rather than a document format.
No. Everything runs in your browser and is discarded when you close the page. Nothing is transmitted to a server, there is no account, and the compounds you compare are not recorded anywhere.
Related Products
Related Research News
Best Peptide Affiliate Program in 2026: 8 Programs Compared by What They Actually Pay
10% flat is the going rate in research peptides, and almost every page quoting it calls it competitive. Eight programs compared on the only four things that decide what you are paid: the rate, the base it is applied to, how long attribution lasts, and when the money actually arrives.
TB-500 vs BPC-157: Evidence, Dosing, Safety Compared
This reference compares TB-500 and BPC-157 across mechanism, dosing, evidence, safety, and pharmacokinetics, highlighting the thin comparative evidence and the need for further study.
Wegovy News: Oral GLP-1 Tracker Shows Novo and Lilly Prescription Growth
New prescription tracking data suggests oral GLP-1 products from Novo Nordisk and Eli Lilly are gaining traction. The latest Wegovy news points to a shifting market for metabolic research compounds, with researchers watching how oral formulations compare to injectable peptides.